XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes to the consolidated financial statements - Summary of upfront payments and related revenues recognized (Details) - Research services combined with an IP license
€ in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2022
EUR (€)
Jun. 30, 2021
EUR (€)
Jun. 30, 2022
USD ($)
Dec. 31, 2021
EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]        
Upfront and milestones payments included in contract liabilities € 120,278     € 142,095
Revenue recognized from upfront and milestones payments 31,818 € 27,731    
CRISPR        
Disclosure of disaggregation of revenue from contracts with customers [line items]        
Upfront payments received or receivable 2,524   $ 3,000  
Upfront and milestones payments included in contract liabilities 1,084     1,239
Revenue recognized from upfront and milestones payments 155 155    
Boehringer Ingelheim        
Disclosure of disaggregation of revenue from contracts with customers [line items]        
Upfront payments received or receivable 30,000      
Revenue recognized from upfront and milestones payments   2,051    
Genmab        
Disclosure of disaggregation of revenue from contracts with customers [line items]        
Upfront payments received or receivable 8,937   $ 10,000  
Upfront and milestones payments included in contract liabilities 4,469     5,362
Revenue recognized from upfront and milestones payments 894 894    
GSK        
Disclosure of disaggregation of revenue from contracts with customers [line items]        
Upfront payments received or receivable 205,000      
Upfront and milestones payments included in contract liabilities 114,725     € 135,494
Revenue recognized from upfront and milestones payments 30,769 € 24,631    
Minimum | GSK        
Disclosure of disaggregation of revenue from contracts with customers [line items]        
Upfront payments received or receivable € 10,000